CEO of Robotic Surgery Leader Sells Shares Worth 20 Billion Won, Also Sold Children's Trust

On January 27, Gary S. Guthart, CEO of robotic‐surgery equipment maker Intuitive Surgical, Inc. (Nasdaq: ISRG), exercised stock options and then sold a portion of both his personally held shares and shares held in trusts for his children, realizing roughly $14 million in cash. On the same day, Chief Medical Officer Myriam Curet exercised a small batch of options and sold them all, converting about $120,000 into cash. Then, on February 10, Vice President of Manufacturing and Supply Chain Mark Brosius saw approximately 400 additional shares vest under his RSU grant. All of these filings were disclosed as routine, scheduled transactions tied to executive compensation and liquidity needs.

In its fourth‐quarter 2025 results announced January 22, Intuitive Surgical reported revenue of $2.87 billion—up about 19% year-over-year—and delivered adjusted EPS of $2.53, ahead of consensus. Global procedure volumes using its da Vinci and Ion robotic platforms rose roughly 18%. For fiscal 2026, the company forecast da Vinci procedure growth of 13–15%, a moderation from recent rates that has prompted some investor concern. Nevertheless, major brokerages including Barclays and RBC continue to recommend buying or overweight positions, with price targets in the upper $600 range.

Intuitive Surgical is the leading provider of minimally invasive surgical robots, best known for its da Vinci surgical system and the Ion platform for lung cancer diagnostics. As of year-end 2025, more than 11,000 da Vinci systems had been placed in hospitals worldwide, where they are used across urology, general surgery and thoracic surgery in the U.S., Europe and Asia.